Navigation Links
Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
Date:10/12/2009

00 million for the exclusive rights to commercialize the oral tablet, which is already approved in the US, in the territory of the US and Canada, as well as to develop and commercialize a depot formulation of Fanapt for patients in this territory. Vanda will be eligible for additional payments upon achieving defined development and commercial milestones and will also receive sales royalties. Vanda will retain rights to develop and commercialize Fanapt outside the territory of US and Canada, but Novartis has the option to enter into discussions with Vanda to co-commercialize Fanapt or receive sales royalties outside this territory. The consummation of the transaction is subject to the receipt of customary regulatory approvals, which are expected by the end of 2009.

Important Safety Information

Fanapt is indicated for the acute treatment of schizophrenia in adults.

Increased Mortality: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death compared to placebo. Fanapt is not approved for the treatment of patients with dementia-related psychosis.

QT Prolongation: In an open-label QTc study in patients with schizophrenia or schizoaffective disorder (N=160), Fanapt was associated with QTc prolongation of 9 msec at an iloperidone dose of 12 mg twice daily. This affect was augmented by the presence of CYP450, 2D6 or 3A4 metabolic inhibition. The use of Fanapt should be avoided in combination with other drugs that are known to prolong QTc. Caution is warranted when prescribing Fanapt with drugs that inhibit Fanapt metabolism.

Neuroleptic Malignant Syndrome (NMS):A potentially fatal symptom complex, has been reported in association with administration of antipsychotic drugs. Clinical manifestations include hyperpyrexia, muscle rigidity, altered mental sta
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
2. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
3. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
4. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
7. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
8. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
9. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
10. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
11. Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014  As physicians seek information about drugs ... to learn about new therapies or ask questions ... new report by global sales and marketing consultants ... via a customized mix of digital media and ... to engage with physicians. And, productive engagement with ...
(Date:9/22/2014)... BARCELONA , España, September 23, 2014 ... nube permite que los patrocinadores de ensayos clínicos satisfagan ... a la accesibilidad y exhaustividad de los expedientes permanentes ... La mayor encuesta sobre TMF en el ... un aumento en el número de patrocinadores de ensayos ...
(Date:9/22/2014)... Calif. , Sept. 22, 2014 Avanir ... that it is offering to sell $200 million of ... Morgan, Deutsche Bank Securities and BofA Merrill Lynch are ... to grant the underwriters a 30-day option to purchase ... shares to be sold in the offering are being ...
Breaking Medicine Technology:As sales reps see doors close for in-person visits with physicians, digital doors open communication 2As sales reps see doors close for in-person visits with physicians, digital doors open communication 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 5El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 2El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 3El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 4El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 5Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3
... N.J., Oct. 31, 2011 Johnson & Johnson Pharmaceutical ... has submitted a supplemental New Drug Application (sNDA) to ... ® ER (tapentadol) extended-release tablets, an oral analgesic, ... peripheral neuropathy (DPN) in adults. The FDA approved NUCYNTA ...
... NEW YORK, Oct. 31, 2011 Reportlinker.com ... is available in its catalogue: ... 2016 http://www.reportlinker.com/p0254518/Germany-Surgical-Equipment-Market-Outlook-to-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment ... to 2016 Summary ...
Cached Medicine Technology:Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 2Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 3Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 4Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 5Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 6Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 7Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 8Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 9Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 10Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 11Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 12Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 13Germany Surgical Equipment Market Outlook to 2016 2Germany Surgical Equipment Market Outlook to 2016 3Germany Surgical Equipment Market Outlook to 2016 4Germany Surgical Equipment Market Outlook to 2016 5Germany Surgical Equipment Market Outlook to 2016 6Germany Surgical Equipment Market Outlook to 2016 7Germany Surgical Equipment Market Outlook to 2016 8Germany Surgical Equipment Market Outlook to 2016 9
(Date:9/23/2014)... 23, 2014 On September 23, 2014, My ... for an episode. Simmons is the founder of Traveler of ... audience would like to know. At the start of the ... to start this magazine?” Simmons replied by saying, “I had ... In 2005, I quit that and decided to start my ...
(Date:9/23/2014)... The U.S. Pharmacopeial Convention (USP) has submitted ... (WHO) regarding the assignment of Biological Qualifiers (BQ) to ... Expert Group of the Programme of International Nonproprietary Names ... naming of all biologicals that is consistent with existing, ... these drugs. , Hence, USP supports the concept ...
(Date:9/23/2014)... Healthcare Solutions, the parent ... and Modern Medical, today announced the expansion ... with EMPLOYERS®, America's small business insurance specialist®. ... has saved millions of dollars in workers’ ... Since May 2013, Healthcare Solutions has worked ...
(Date:9/23/2014)... 2014 (HealthDay News) -- Fear of losing your job can ... European study. The study involved more than 7,000 employed ... downturn in Europe, the workers answered questions about the respiratory ... their job within two years. More than 100 new ... of whom were women, during the study period. The ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Altec ... and workflow solutions, will be a participating sponsor ... annual Microsoft Dynamics® GP customer conference, from 8:00am ... Meydenbauer Center in Bellevue, Washington. The Resource Group ... overcome challenges during growth and connect disparate ...
Breaking Medicine News(10 mins):Health News:My Positive Perspective Airs Episode With the Founder of Traveler of Charleston Magazine 2Health News:USP Comments to WHO Regarding Biologics Qualifier Proposal 2Health News:EMPLOYERS® Expands Pharmacy Services with Healthcare Solutions After Effective Pilot Program 2Health News:EMPLOYERS® Expands Pharmacy Services with Healthcare Solutions After Effective Pilot Program 3Health News:Job Worries Can Raise Asthma Risk, Study Says 2Health News:Altec to Sponsor The Resource Group’s Annual RG Connect Conference 2Health News:Altec to Sponsor The Resource Group’s Annual RG Connect Conference 3
... can be severe , , MONDAY, May 18 (HealthDay News) -- ... as it tries to serve the poor, researchers from North ... recovering from breast cancer do not take the drugs ... do not follow instructions to take these drugs, medications that ...
... CLC 27th Annual Conference on Professional Issues May 24 in ... Council, the leading nonprofit professional association serving child life specialists, ... recipient of the 2009 Distinguished Service Award, in recognition of ... Utica College was selected by ...
... retail locationNORTH BERGEN, N.J., May 18 Eco Shoppe has announced ... Eco Shoppe store in the country. Eco Shoppe is a ... products directly to consumers through exciting new stores as well as ... will open in Austin on May 21 and is owned and ...
... made on May 13, 2009, as Minnesota became the ... health provider into state statute - enabling students who ... model to become licensed to practice. The Minnesota ... a bill establishing the Dental Therapist and Advanced Dental ...
... Study Confirms Previous Positive Findings on Efficacy and ... Deutsche Bank 34th Annual Healthcare Conference Today at ... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... from its Phase IIb clinical trial known as ...
... study finds , , MONDAY, May 18 (HealthDay News) -- People ... chance of living a longer and healthier life. , Researchers ... data from 2002 to 2007, found that that wealthier people ... were less likely to have depression, high-blood pressure or diabetes ...
Cached Medicine News:Health News:Poor Women Seem to Be Skipping Breast Cancer Drugs 2Health News:Utica College to Receive Child Life Council Spirit of Giving Award 2Health News:Utica College to Receive Child Life Council Spirit of Giving Award 3Health News:First Eco Shoppe Opening in Austin on May 21 2Health News:First Eco Shoppe Opening in Austin on May 21 3Health News:First Eco Shoppe Opening in Austin on May 21 4Health News:Minnesota Passes Legislation Allowing Mid-level Oral Health Provider 2Health News:Minnesota Passes Legislation Allowing Mid-level Oral Health Provider 3Health News:Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain 2Health News:Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain 3Health News:Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain 4Health News:Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain 5Health News:Money May Matter, Health-Wise, in Old Age 2
... GE Healthcare is ... in best-in-class analysis programs ... area monitoring device. With ... 12SL, Gender-Specific, and ACI-TIPI, ...
... The Affinity pacemaker family ... smallest, truly automatic devices. ... combination of advanced technologies ... DR pacemaker incorporates the ...
... small bench top chemistry analyzer that utilizes dry ... with results available within 8 - 15 minutes. ... instrument accepts whole blood samples and is calibrated ... At the conclusion of testing, results are available ...
... is a battery-backed up, microprocessor based, quality instrument ... It stores and displays a chart on its ... scrolled through or zoomed into and out of, ... to 3 months can be seen at one ...
Medicine Products: